BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34507826)

  • 1. Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
    Qin J; Shahangian S; Saraiya M; Holt H; Gagnon M; Sawaya GF
    Gynecol Oncol; 2021 Nov; 163(2):378-384. PubMed ID: 34507826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study.
    Maura G; Chaignot C; Weill A; Alla F; Heard I
    Eur J Cancer Prev; 2018 Sep; 27(5):479-485. PubMed ID: 28368950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort.
    Mills JM; Morgan JR; Dhaliwal A; Perkins RB
    Gynecol Oncol; 2021 Aug; 162(2):308-314. PubMed ID: 34090706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
    Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
    J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
    Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical testing beyond the screening target age - A register-based cohort study from Finland.
    Keltto N; Leivonen A; Pankakoski M; Sarkeala T; Heinävaara S; Anttila A
    Gynecol Oncol; 2021 Aug; 162(2):315-321. PubMed ID: 34074539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
    Li Z; Austin RM; Guo M; Zhao C
    Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Acceptability and Preference of Vaginal Self-sampling for Human Papillomavirus (HPV) Testing among a Multi-ethnic Asian Female Population.
    Khoo SP; Lim WT; Rajasuriar R; Nasir NH; Gravitt P; Woo YL
    Cancer Prev Res (Phila); 2021 Jan; 14(1):105-112. PubMed ID: 32917643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.
    Cuzick J; Du R; Adcock R; Kinney W; Joste N; McDonald RM; English K; Torres SM; Saslow D; Wheeler CM;
    Gynecol Oncol; 2021 Sep; 162(3):555-559. PubMed ID: 34253387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
    Hortlund M; Mühr LSA; Lagheden C; Hjerpe A; Dillner J
    Int J Cancer; 2021 Dec; 149(12):2083-2090. PubMed ID: 34418082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use Trends and Recent Expenditures for Cervical Cancer Screening-Associated Services in Medicare Fee-for-Service Beneficiaries Older Than 65 Years.
    Qin J; Holt HK; Richards TB; Saraiya M; Sawaya GF
    JAMA Intern Med; 2023 Jan; 183(1):11-20. PubMed ID: 36409511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
    Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
    Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
    Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
    J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence and determinants of cervical cancer screening with a combination of cytology and human papillomavirus testing.
    Fokom Domgue J; Cunningham SA; Yu RK; Shete S
    Ann Epidemiol; 2019 Aug; 36():40-47. PubMed ID: 31320153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2018 Aug; 320(7):674-686. PubMed ID: 30140884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014.
    Wright JD; Chen L; Tergas AI; Melamed A; St Clair CM; Hou JY; Khoury-Collado F; Gockley A; Accordino M; Hershman DL
    JAMA Netw Open; 2021 Apr; 4(4):e218373. PubMed ID: 33914050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.
    Silver MI; Rositch AF; Phelan-Emrick DF; Gravitt PE
    Cancer Causes Control; 2018 Jan; 29(1):43-50. PubMed ID: 29124542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Squamous cell carcinoma of the cervix: a cytology-histology-human papillomavirus correlation in clinical practice.
    Miller RA; Waters LL; Mody DR; Tams KC
    Arch Pathol Lab Med; 2015 Jun; 139(6):776-81. PubMed ID: 26030246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
    Munshi VN; Perkins RB; Sy S; Kim JJ
    Am J Obstet Gynecol; 2022 Feb; 226(2):228.e1-228.e9. PubMed ID: 34547295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.
    Kim JJ; Burger EA; Regan C; Sy S
    JAMA; 2018 Aug; 320(7):706-714. PubMed ID: 30140882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.